Pharma & Biotech M&A Tracker
117
July 2026
GTM
Confirmed pharmaceutical and biotech mergers, acquisitions, and licensing deals above $100M, structured each month from company press releases, SEC filings, and pharma trade press. Each record includes the acquirer, acquired company or asset, deal type (acquisition, merger, or licensing), therapeutic area, deal stage, deal value, currency, and announcement date. Coverage spans global transactions involving publicly listed and private companies across oncology, rare diseases, immunology, neurology, and emerging therapeutic areas.
Pharmaceutical or biotech company acquisition, merger, or licensing deal above $100M announced in the last month
Pharma business development and licensing teams use it to track competitor deal activity and identify active acquirers in specific therapeutic areas. Private equity and venture investors monitor it for sector consolidation signals. Equity analysts covering healthcare use it to benchmark deal multiples and M&A volume. Competitive intelligence teams track pipeline asset movements across companies.
1071
<table class="catchall-table"><thead><tr><th style="min-width:40px">#</th><th style="min-width:280px">Event</th><th style="min-width:160px">Deal Currency</th><th style="min-width:160px">Acquirer Company</th><th style="min-width:160px">Deal Stage</th><th style="min-width:160px">Acquired Company</th><th style="min-width:160px">Deal Date</th><th style="min-width:160px">Therapeutic Area</th><th style="min-width:160px">Deal Type</th><th style="min-width:160px">Deal Amount</th></tr></thead><tbody><tr><td style="min-width:40px">1</td><td style="min-width:280px">Eli Lilly announces acquisition of AtaiBeckley</td><td style="min-width:160px">USD</td><td style="min-width:160px">Eli Lilly and Company</td><td style="min-width:160px">announced</td><td style="min-width:160px">AtaiBeckley</td><td style="min-width:160px">2026-07-16</td><td style="min-width:160px">psychedelic assets</td><td style="min-width:160px">acquisition</td><td style="min-width:160px">3,800,000,000</td></tr><tr><td style="min-width:40px">2</td><td style="min-width:280px">Tilray Brands Acquires HelloMD for Medical Cannabis Expansion</td><td style="min-width:160px">USD</td><td style="min-width:160px">Tilray Brands</td><td style="min-width:160px">announced</td><td style="min-width:160px">HelloMD</td><td style="min-width:160px">2026-07-02</td><td style="min-width:160px">medical cannabis</td><td style="min-width:160px">acquisition</td><td style="min-width:160px">100,000,000</td></tr><tr><td style="min-width:40px">3</td><td style="min-width:280px">Laprophan acquires Rivopharm</td><td style="min-width:160px">USD</td><td style="min-width:160px">Laprophan Group</td><td style="min-width:160px">completed</td><td style="min-width:160px">Rivopharm</td><td style="min-width:160px">2026-07-03</td><td style="min-width:160px">antibiotic, antidepressant, anti-inflammatory therapies, epilepsy, angina</td><td style="min-width:160px">acquisition</td><td style="min-width:160px">100,000,000</td></tr><tr><td style="min-width:40px">4</td><td style="min-width:280px">Nova Biomedical acquires NanoCellect assets</td><td style="min-width:160px">USD</td><td style="min-width:160px">Nova Biomedical</td><td style="min-width:160px">announced</td><td style="min-width:160px">NanoCellect</td><td style="min-width:160px">2026-07-24</td><td style="min-width:160px">cell line development</td><td style="min-width:160px">acquisition</td><td style="min-width:160px">100,000,000</td></tr><tr><td style="min-width:40px">5</td><td style="min-width:280px">Codis acquires Catalent's Nottingham facility</td><td style="min-width:160px">USD</td><td style="min-width:160px">Codis</td><td style="min-width:160px">pending_approval</td><td style="min-width:160px">Catalent Pharma Solutions</td><td style="min-width:160px">2026-07-06</td><td style="min-width:160px">oral solid dose development, bioavailability enhancement</td><td style="min-width:160px">acquisition</td><td style="min-width:160px">2,500,000,000</td></tr><tr class="catchall-blurred"><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td></tr><tr class="catchall-blurred"><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td></tr><tr class="catchall-blurred"><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td><td>████████████</td></tr></tbody></table>
<h3>What deal types are included?</h3><p>Acquisitions, mergers, and licensing deals above $100M. Asset purchases and divestitures are included where the transaction value exceeds the threshold. Early-stage collaboration agreements without disclosed upfront payments are excluded.</p><h3>Are licensing deals included alongside acquisitions?</h3><p>Yes. Licensing agreements with an upfront payment or total deal value above $100M are included. Milestone-only deals without a disclosed upfront component are excluded.</p><h3>How does this differ from industry databases like Evaluate Pharma or Citeline?</h3><p>Those databases rely on direct company reporting networks. CatchAll extracts confirmed transactions from news sources, press releases, and SEC filings as structured events, with a source link for each record.</p><h3>What is the refresh rate of this dataset?</h3><p>We rerun this dataset once a month. You can create your own dataset that updates as frequently as every one hour on <a href="https://platform.newscatcherapi.com/catchall">platform.newscatcherapi.com/catchall</a></p>